Last reviewed · How we verify
GV20-0251 and Pembrolizumab [KEYTRUDA®]
At a glance
| Generic name | GV20-0251 and Pembrolizumab [KEYTRUDA®] |
|---|---|
| Also known as | MK-3475 |
| Sponsor | GV20 Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GV20-0251 and Pembrolizumab [KEYTRUDA®] CI brief — competitive landscape report
- GV20-0251 and Pembrolizumab [KEYTRUDA®] updates RSS · CI watch RSS
- GV20 Therapeutics portfolio CI